Payment overview · 2025
General Payments
$3,053.68
149 reported records · 30 companies
Healthcare provider profile · identity verified
Rebecca E Johnson, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · SPOKANE, WA · NPI 1083864045
Verified facts
What the public records show
CMS Open Payments records show Rebecca E Johnson, PA-C received $3,053.68 in general payments during 2025 across 149 reported records.
ABBVIE INC. accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $477.30 | 15.6% | 23 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $400.40 | 13.1% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $289.70 | 9.5% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $196.94 | 6.5% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $181.68 | 6.0% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $162.88 | 5.3% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $140.71 | 4.6% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $137.24 | 4.5% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $130.59 | 4.3% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $91.94 | 3.0% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $84.48 | 2.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.02 | 2.6% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$77.32 | 2.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.17 | 1.8% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.81 | 1.8% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $50.52 | 1.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $49.48 | 1.6% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.52 | 1.6% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $40.81 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.94 | 1.3% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $36.80 | 1.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $36.34 | 1.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.17 | 1.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.43 | 1.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.74 | 1.0% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.05 | 0.8% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $21.41 | 0.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $15.60 | 0.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.30 | 0.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.39 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,915.70 | 147 |
| Education | $137.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $262.24 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $254.36 | 12 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $227.65 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $220.73 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $180.92 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $166.76 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $130.59 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $130.53 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $128.44 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $98.26 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $91.94 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $91.67 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $90.01 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $90.01 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $87.24 | 7 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $84.48 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $83.48 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $78.40 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $74.33 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $74.33 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.92 | 6 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $57.19 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.17 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $54.81 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $52.83 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $50.52 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $49.48 | 2 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $48.52 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $47.90 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $40.81 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.99 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.94 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $36.80 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $36.34 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $34.77 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.43 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| PRESTIGE LP CERVICAL DISC SYSTEM Normalized: prestige lp cervical disc system |
Device | Medtronic, Inc. | $29.42 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $26.24 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $25.05 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.63 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.93 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 72 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 94 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 90 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 645 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 412 | 124 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 368 | 97 |
| Lisinopril | Lisinopril | 301 | 84 |
| Losartan Potassium | Losartan Potassium | 288 | 72 |
| Omeprazole | Omeprazole | 242 | 67 |
| Gabapentin | Gabapentin | 238 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 196 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 38 |
| Metformin Hcl | Metformin Hcl | 157 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 42 |
| Simvastatin | Simvastatin | 135 | 38 |
| Trazodone Hcl | Trazodone Hcl | 134 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 121 | 35 |
| Sertraline Hcl | Sertraline Hcl | 121 | 24 |
| Potassium Chloride | Potassium Chloride | 114 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 33 |
| Alendronate Sodium | Alendronate Sodium | 103 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 27 |
| Furosemide | Furosemide | 99 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 25 |
| Jardiance | Empagliflozin | 94 | 29 |
| Metformin Hcl Er | Metformin Hcl | 90 | 27 |
| Mounjaro | Tirzepatide | 90 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 36 |
| Famotidine | Famotidine | 80 | 23 |
| Allopurinol | Allopurinol | 79 | 23 |
| Tramadol Hcl | Tramadol Hcl | 79 | 27 |
| Spironolactone | Spironolactone | 77 | 23 |
| Alprazolam | Alprazolam | 74 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 23 |
| Eliquis | Apixaban | 72 | 20 |
| Gemfibrozil | Gemfibrozil | 71 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 21 |
| Lorazepam | Lorazepam | 61 | 19 |
| Bupropion Xl | Bupropion Hcl | 58 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 15 |
| Topiramate | Topiramate | 58 | suppressed |
| Xarelto | Rivaroxaban | 57 | 16 |
| Ozempic | Semaglutide | 56 | 11 |
| Propranolol Hcl | Propranolol Hcl | 56 | 11 |
| Olanzapine | Olanzapine | 55 | suppressed |
| Pregabalin | Pregabalin | 55 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 38 |
| Morphine Sulfate Er | Morphine Sulfate | 54 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 13 |
| Lovastatin | Lovastatin | 53 | 11 |
| Acyclovir | Acyclovir | 51 | suppressed |
| Glipizide Er | Glipizide | 51 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 16 |
| Atenolol | Atenolol | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 15 |
| Aripiprazole | Aripiprazole | 47 | 11 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 36 |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Methocarbamol | Methocarbamol | 43 | 15 |
| Donepezil Hcl | Donepezil Hcl | 42 | 11 |
| Glipizide | Glipizide | 42 | 13 |
| Sucralfate | Sucralfate | 42 | suppressed |
| Meloxicam | Meloxicam | 40 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 16 |
| Morphine Sulfate | Morphine Sulfate | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Estradiol | Estradiol | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 17 |
| Carvedilol | Carvedilol | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 33 | suppressed |
| Nystatin | Nystatin | 33 | 18 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Baclofen | Baclofen | 30 | 11 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Prednisone | Prednisone | 30 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Cephalexin | Cephalexin | 25 | 18 |
| Methadone Hcl | Methadone Hcl | 25 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ambien | Zolpidem Tartrate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,053.68 · 149 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AUSTEDO XR, BREZTRI, Belbuca, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, FANAPT, FARXIGA, GEMTESA, INGREZZA, INVEGA SUSTENNA, JARDIANCE, Kerendia, LEQVIO, LINZESS, MAVYRET, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PRESTIGE LP CERVICAL DISC SYSTEM, PREVNAR 20, Prolastin-C Liquid, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, UZEDY, VRAYLAR, Veozah, WATCHMAN FLX, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error